Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The BRCA2 gene is mutated in familial breast and ovarian cancer, and its product is implicated in DNA repair and transcriptional regulation. Here we identify a protein, EMSY, which binds BRCA2 within a region (exon 3) deleted in cancer. EMSY is capable of silencing the activation potential of BRCA2 exon 3, associates with chromatin regulators HP1beta and BS69, and localizes to sites of repair following DNA damage. EMSY maps to chromosome 11q13.5, a region known to be involved in breast and ovarian cancer. We show that the EMSY gene is amplified almost exclusively in sporadic breast cancer (13%) and higher-grade ovarian cancer (17%). In addition, EMSY amplification is associated with worse survival, particularly in node-negative breast cancer, suggesting that it may be of prognostic value. The remarkable clinical overlap between sporadic EMSY amplification and familial BRCA2 deletion implicates a BRCA2 pathway in sporadic breast and ovarian cancer.


Journal article



Publication Date





523 - 535


BRCA2 Protein, Base Sequence, Breast Neoplasms, Carcinoma, Carrier Proteins, Chromosomal Proteins, Non-Histone, Chromosomes, Human, Pair 11, DNA, Complementary, Exons, Female, Gene Amplification, Gene Silencing, Genes, Regulator, Genetic Predisposition to Disease, Humans, Molecular Sequence Data, Neoplasm Proteins, Nuclear Proteins, Ovarian Neoplasms, Phylogeny, Plant Proteins, Prognosis, Protein Structure, Tertiary, Repressor Proteins, Signal Transduction